Pfizer’s Maddaluna retiring as head of global supply after 41 years with the company

Anthony J. Maddaluna

Pfizer’s executive vice president and president of global supply, Anthony J. Maddaluna, is retiring from the pharma giant after more than 41 years with the company.

Maddaluna first started with Pfizer in 1975 and worked his way up the ranks, holding a number of key positions during his career. He was named president of global supply in 2011, the company said.

“I have had the privilege of working with Tony during much of his career, and he has been a valuable partner to me,” Ian Read, Pfizer’s chairman and chief executive officer, said in a statement. “Tony has continually demonstrated a steadfast commitment to Pfizer and our mission.”

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Kirsten Lund-Jurgensen has been named to succeed Maddaluna, effective at the end of the year. She is currently vice president of innovative health product portfolio management and consumer operations.

Prior to joining Pfizer in 1999, Lund-Jurgensen was with SmithKline Beecham, where she held several positions with operational responsibilities.

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.